Potent and selective L-type voltage-gated Ca2+ channel blocker. EC50 and pA2 values are 1.4 nM and 10.3 for relaxation of depolarization- and Ca2+-induced contractions of rabbit aorta respectively; EC25 = 0.45 nM for reduction in rate of spontaneously beating guinea pig right atria. Long-acting antihypertensive agent in vivo, exerting primary effects on vascular tissue with secondary negative chronotropic action.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 371.39. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.39 mL||26.93 mL||53.85 mL|
|2.5 mM||1.08 mL||5.39 mL||10.77 mL|
|5 mM||0.54 mL||2.69 mL||5.39 mL|
|25 mM||0.11 mL||0.54 mL||1.08 mL|
References are publications that support the biological activity of the product.
Hof et al (1984) PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta. J.Cardiovasc.Pharmacol. 6 399 PMID: 6202964
Wada et al (1985) Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart. J.Cardiovasc.Pharmacol. 7 190 PMID: 2580142
Ruegg and Hof (1990) Pharmacology of the calcium antagonist isradipine. Drugs 40 3
If you know of a relevant reference for Isradipine, please let us know.
View Related Products by Product Action
Keywords: Isradipine, Isradipine supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, voltage-gated, voltage-dependent, PN200110, PN, 200-110, Voltage-gated, 2004, Tocris Bioscience
4 Citations for Isradipine
Citations are publications that use Tocris products. Selected citations for Isradipine include:
Pourbadie et al (2015) Preventing effect of L-type calcium channel blockade on electrophysiological alterations in dentate gyrus granule cells induced by entorhinal amyloid pathology. J Neurosci 10 e0117555 PMID: 25689857
Saszik and DeVries (2012) A mammalian retinal bipolar cell uses both graded changes in membrane voltage and all-or-nothing Na+ spikes to encode light. J Neurosci 32 297 PMID: 22219291
Dragicevic et al (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. PLoS One 137 2287 PMID: 24934288
Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728
Do you know of a great paper that uses Isradipine from Tocris? Please let us know.
Reviews for Isradipine
There are currently no reviews for this product. Be the first to review Isradipine and earn rewards!
Have you used Isradipine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.